KLOW
KLOW extends the GLOW regeneration concept with KPV — a tripeptide fragment of α-MSH studied for its anti-inflammatory and dermal-barrier modulation activity.
- Vial Size
- 80mg
- Molecular Weight
- Blend · 80 mg total payload (5:1:1:1)
- Half-life
- Mixed pharmacokinetics across components
- Latest Lot Purity
- 99.79%
Mechanism of Action
KLOW extends the GLOW regeneration concept with KPV — a tripeptide fragment of α-MSH studied for its anti-inflammatory and dermal-barrier modulation activity. The four-peptide matrix is intended for advanced regeneration and inflammation research protocols.
Research Context
- Inflammatory pathway research
- Dermal barrier and wound repair models
- α-MSH receptor signalling studies
- Multi-pathway recovery protocol design
Lot NX-010 · Verified at 99.79%
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for KLOW.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the KLOW monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 350–700 mcg blend
- Frequency
- Once daily
- Cycle Length
- 4–6 weeks
- Route
- Subcutaneous
Note ·Adds KPV inflammation-modulation to the GLOW base.
Related Compounds
All compounds →
BPC 157
Research peptide used across tissue and recovery models.
TB 500
Thymosin beta fragment for connective tissue and repair studies.
GLOW
Three-peptide regeneration blend · BPC-157 + TB-500 + GHK-Cu
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.